CYTOKINETICS INC — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Cytokinetics reported Q2 2026 net product revenue of $25.3M ($23.0M U.S., $2.3M Europe) from MYQORZO (aficamten) with 1,500 patients dispensed and 700+ prescribing providers as of June 30. The company completed a public offering of 11,338,028 shares at $71/share, raising $760.1M net proceeds, bringing cash to $1.7B. ACACIA-HCM Phase 3 trial met dual primary endpoints in non-obstructive HCM; supplemental NDA planned Q4 2026. Net loss widened to $198.8M (Q2 2026) vs. $134.4M (Q2 2025), driven by commercial launch SG&A costs ($104.4M vs. $65.7M YoY). Full-year 2026 guidance raised to $860–$890M combined R&D+SG&A.
Why this rating
Successful commercial launch and positive late-stage data are trajectory-affirming; $760M capital raise (30% of market cap) and $1.7B cash runway reduce near-term risk materially. Offset by widening net losses and elevated burn. Moderate-to-significant for a $2.5B biotech in commercialization phase.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.